More specifically, PSMA-targeting therapeutic agents may selectively destroy vessels perfusing tumor tissue and achieve high regional doses of drugs to overcome tumor resistance while sparing normal tissue, which typically lacks PSMA expression. This evidence concerns the gene FOLH1 and neoplasm.